Broadcom named strategic vendor for Walmart virtualization solutions
BRANFORD, Conn. - Quantum-Si Incorporated (NASDAQ:QSI), known as The Protein Sequencing Company™, has announced the commencement of worldwide shipments for its Platinum® Pro benchtop sequencer, a device designed for high-precision protein analysis. The launch of Platinum Pro marks a significant step in the company’s efforts to make Next-Gen Protein Sequencing™ more accessible to laboratories around the globe. According to InvestingPro data, the company’s revenue grew by an impressive 182% in the last twelve months, though it maintains a modest market capitalization of $258 million. InvestingPro analysis suggests the stock is currently undervalued based on its Fair Value model.
The new system builds on the technology of its predecessor, the original Platinum, and introduces enhanced features to meet the needs of researchers and biopharmaceutical companies. Among the key advancements are a more user-friendly experience with an enlarged touchscreen, options for both local and cloud-based data analysis, and a Pro Mode that allows for the development of custom applications through a Technology Access Program. InvestingPro analysis reveals the company maintains a strong liquidity position with a current ratio of 11.99, indicating robust short-term financial health despite recent market volatility.
Quantum-Si’s President and CEO, Jeff Hawkins, emphasized the company’s dedication to advancing proteomics research, stating that the Platinum Pro is equipped with additional functionalities to enable new insights and potentially lead to the discovery of novel biomarkers in the future. While the stock has experienced a significant 56% gain over the past six months, InvestingPro subscribers have access to 12 additional investment tips and comprehensive analysis for QSI, including detailed cash flow metrics and growth projections.
The Platinum Pro system is now available in over 30 countries through Quantum-Si’s direct and channel partner network. The company’s product line aims to propel proteomic research, drug discovery, and diagnostics beyond the capabilities of current proteomic tools. Financial data shows the company holds more cash than debt on its balance sheet, providing financial flexibility for its global expansion efforts.
This announcement comes with the usual caveats of forward-looking statements, which are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. Factors influencing these potential outcomes include market adoption, regulatory approval, and the ability to maintain Nasdaq listing, among others. With analysts anticipating continued sales growth and the next earnings report due on May 8, 2025, investors can access detailed financial projections and comprehensive analysis through QSI’s Pro Research Report, available exclusively on InvestingPro.
Quantum-Si’s focus on revolutionizing proteomics is underscored by its commitment to delivering innovative solutions for protein sequencing. The information reported is based on a press release statement from Quantum-Si Incorporated.
In other recent news, QuantumSi Inc. reported its fourth-quarter 2024 earnings, revealing a wider-than-expected loss per share and lower-than-anticipated revenue. The company posted an actual EPS of -$0.23, missing the forecast of -$0.19, and reported revenue of $1.2 million, below the expected $1.79 million. Despite a 52% revenue increase from the previous quarter, the figures fell short of market expectations. QuantumSi launched a new product, Platinum Pro, in January 2025 and plans to introduce its Proteus platform in the second half of 2026. The company raised an additional $50 million in January 2025, which, along with existing funds, is expected to extend its cash runway into the second half of 2027. QuantumSi is also expanding its international distribution network, having established 18 partners by the end of 2024. Analysts from Canaccord Genuity and H.C. Wainwright have shown interest in the company’s commercial strategy and technology advancements. QuantumSi remains focused on strategic partnerships and R&D initiatives to drive growth in the proteomics market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.